No Data
Inhibikase Therapeutics Files to Sell 58.31M Shares of Common Stock for Holders
Express News | Inhibikase Therapeutics Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After Reporting Worse-than-expected Q3 EPS Results Yesterday
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5
Inhibikase Therapeutics' Promising Developments and Financial Backing Justify Buy Rating
Inhibikase Therapeutics GAAP EPS of -$0.65 Misses by $0.17
Inhibikase Therapeutics Secures Up to $275 Million in Financing to Advance IkT-001Pro Into Late-Stage Clinical Trials for Pulmonary Arterial Hypertension
No Data
No Data
